Rating Change
HC Wainwright & Co. reiterated its Neutral rating on Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) on October 26, 2026.
reiterateNASDAQ:AARD
HC Wainwright & Co. Reiterates Neutral Rating on Aardvark Therapeutics, Inc. Common Stock (AARD)
HC Wainwright & Co. reiterated its Neutral rating on Aardvark Therapeutics, Inc.
At publication ·
What changed
Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Neutral to Neutral
- Price at event
- $1.06
- Market capitalization
- $271.9M
At a glance
Key takeaways
- HC Wainwright & Co. maintained a Neutral rating on Aardvark Therapeutics (AARD) on October 26, 2026, with no price target provided.
Market Context
Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $1.05 with a market capitalization of $271.9M. The stock has declined 87.3% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Aardvark Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Aardvark Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 4 Buy, 5 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 26, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Oct 19, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Sep 24, 2026 | RBC Capital | Sector Perform | N/A |
| Jul 20, 2026 | HC Wainwright & Co. | Neutral | N/A |
| May 15, 2026 | Morgan Stanley | Underweight | N/A |
Related Tools: Analyst Ratings Dashboard | View AARD Stock Page
Frequently Asked Questions
What does the Neutral rating mean for AARD?
A rating of Neutral from HC Wainwright & Co. reflects the analyst's outlook on Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AARD forecast page.